reference/28416742

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/28416742

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't
endingPage	684
issn	1365-2893 1352-0504
issueIdentifier	6
pageRange	675-684
publicationName	Journal of Viral Hepatitis
startingPage	675
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_f3adb2487eb1d8d5b24b68a3e156f5fb http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_1d33dbd06de50e8e836027ea8a1f4aeb
bibliographicCitation	Lawitz E, Poordad F, Anderson LJ, Vesay M, Kelly MM, Liu H, Gao W, Fernsler D, Asante‐Appiah E, Robertson MN, Hanna GJ, Barr E, Butterton J, Kowdley KV, Hassanein T, Sahota A, Gordon SC, Yeh WW. Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. Journal of Viral Hepatitis. 2019 Mar 12;26(6):675–84. doi: 10.1111/jvh.13079.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_072312988700018c7753fe2de7f40fa3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e6d822ea56dfcc186d074ca2549b641 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f68f7a1a178f822b56287a1f7413e81f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c8b4d8ab5d6548d83e2e84a6669bed4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fc8b13c00622785206eb2cc28a45daa4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3b43a1213a9840cef22f6475e12519eb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_61b7f5ecbc7d025d7f12f9fceec608e9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0bda816700808a8a249aa4d2ebd45225 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bdeabaaf0877dda9168c36c9781f23ec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb530bad5ad88764ee0c10914aa739ce http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dfcf2625018812afce4010a4945278f5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_618c9c12c184f5aabd8366188953378e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_55043c1bae1d109e9b7798f3143d3e41 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8566df2226b09eb9f2b4bdd46ec916ec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eda1a25cacdb04f0c0466f2641bb0114 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_900cf870eb28ef77e86bc14d1cbd5b36 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4234-224X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2f1f61e1ffaa8b7160f9614685a1d0f6
date	2019-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/30739366 https://doi.org/10.1111/jvh.13079
isPartOf	https://portal.issn.org/resource/ISSN/1365-2893 https://portal.issn.org/resource/ISSN/1352-0504 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8796
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection
discusses	http://id.nlm.nih.gov/mesh/M0001518 http://id.nlm.nih.gov/mesh/M000634760 http://id.nlm.nih.gov/mesh/M000643998 http://id.nlm.nih.gov/mesh/M0010295 http://id.nlm.nih.gov/mesh/M0021333 http://id.nlm.nih.gov/mesh/M0022344 http://id.nlm.nih.gov/mesh/M0018277
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D019698Q000188 http://id.nlm.nih.gov/mesh/D011759Q000008 http://id.nlm.nih.gov/mesh/D000998Q000008 http://id.nlm.nih.gov/mesh/D014529Q000031 http://id.nlm.nih.gov/mesh/D013844Q000008 http://id.nlm.nih.gov/mesh/D006576Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D004359 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000998Q000627 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D014529Q000008 http://id.nlm.nih.gov/mesh/D014529Q000627 http://id.nlm.nih.gov/mesh/D016174Q000187 http://id.nlm.nih.gov/mesh/D006576Q000627 http://id.nlm.nih.gov/mesh/D011759Q000627 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D005838 http://id.nlm.nih.gov/mesh/D013844Q000627 http://id.nlm.nih.gov/mesh/D016174Q000235 http://id.nlm.nih.gov/mesh/D000072230
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID90055716 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7507 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID37542 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID91936863 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID75104755 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_98958a63de36ab460240c5e11868eb68 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10399 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44603531 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_aeebd1980c6662678028fc899ba441eb http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.6.1.1 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_dc9cf8b3879ed33e4a0441279ba2adb8 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e906efeb92c912342305574e6de5bb5d http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_660b428645036f443f55711551d54a3c

Total number of triples: 84.